LY900021 (Eli Lilly and Company)

LY900021 is a subcutaneous co-formulation developed by Eli Lilly and Company, consisting of the interleukin-23 (IL-23) inhibitor mirikizumab (LY3074828) and recombinant human hyaluronidase (rHuPH20). Mirikizumab is a humanized IgG4 monoclonal antibody that selectively targets the p19 subunit of IL-23, thereby blocking the IL-23/IL-17 inflammatory axis which is central to the pathogenesis of several autoimmune conditions. The inclusion of rHuPH20, a Halozyme ENHANZE technology component, serves to transiently degrade hyaluronan in the extracellular matrix of the subcutaneous tissue. This action increases tissue permeability, allowing for the administration of larger volumes of the therapeutic antibody and potentially improving patient comfort and absorption. LY900021 is primarily being investigated for the treatment of ulcerative colitis, Crohn's disease, and plaque psoriasis.

Other names

mirikizumab + hyaluronidasemirikizumab + rHuPH20